People & Organization

Søren Tulstrup has served as President and Chief Executive Officer since March 2018. He has extensive experience as a senior executive in the global biopharma industry. Prior to joining Hansa, he served as Chief Executive Officer of Vifor Pharma AG (SIX: VIFN), (now part of CSL Behring), a Glattbrugg, Switzerland-based global pharmaceutical company. Søren also previously served as Chief Executive Officer of Santaris Pharma A/S (now part of F. Hoffmann-La Roche AG, or Roche (SIX: ROG)), a leading clinical stage biopharmaceutical Company developing RNA-targeted drugs for various therapeutic areas including rare genetic diseases. Furthermore, Søren has served in several senior general management and commercial roles within Shire Pharmaceuticals (now The Takeda Pharmaceutical Company Limited (TSE: 4502)), Merck & Co., Inc. (NYSE: MRK) and Sandoz Pharma AG (now Novartis AG, or Novartis (NYSE: NVS)) in both Europe and the United States. He holds a Master of Science, Economics and Business Administration from Copenhagen Business School. He was born in 1965.

Shareholding: 26,541

Donato Spota has served as Chief Financial Officer since May 2019. Donato brings more than 20 years of pharmaceutical industry experience in international environments, including strategic finance, business development, investor relations and international capital markets transactions to the Company. Prior to joining Hansa, he served in various roles at Basilea Pharmaceutica AG, or Basilea (SIX: BSLN), including as Chief Financial Officer from November 2013 to April 2019. He holds a B.A. in Information Technology from the Swiss BBT (Bundesamt für Berufsbildung und Technologie) and an M.B.A. from the Hochschule für Wirtschaft und Umwelt Nürtingen-Geislingen. He was born in 1971.

Shareholding: 5,673

Eva Nilsagård has served as a member of the Board and chair of the Audit Committee since May 2019. Since July 2015, Eva has served as the founder and Chief Executive Officer of Nilsagård Consulting AB. She previously served as interim Chief Financial Officer of various companies, including OptiGroup AB from January 2019 to October 2019 and April 2020 to December 2020, Plastal from September 2016 to September 2017, and Vitrolife AB (STO: VITR) from March 2009 to August 2010. She also served in various senior positions at the Volvo Group, or Volvo (STO: VOLV), including Senior Vice President Strategy & Business Development from September 2010 to June 2014. Earlier in her career, Eva also held senior positions in finance and business development at AstraZeneca plc (LSE: AZN) and AB SKF (STO: SKF). She is a board member and chair of the audit committee of SEK (Swedish Export Credit Company), AddLife (STO: ALIF), Bufab Group (STO: BUFAB), Irras AB (STO: IRRAS), Nimbus Group AB (STO: BOAT), Nanexa (STO: NANEXA) and Xbrane Biopharma (STO: XBRANE), the chair of Spermosens AB (Spotlight: SPERM) and Diagonal Bio AB (STO: DIABIO), and a board member of eEducation Albert AB (STO: ALBERT). Eva has more than ten years of experience as a mentor for young female managers with high potential. She holds an Executive M.B.A. in Economics and a B.Sc. in accounting and finance from School of Business, Economics and Law in Gothenburg. She was born in 1964.

Eva is Chairman of Hansa Biopharma’s Audit Committee. Independent of Hansa Biopharma and its executive management. Independent of major shareholders of Hansa Biopharma.

Shareholding: 3,000

Mats Blom has served as a member of the Board since May 2019. Mats has served as the Chief Financial Officer of NorthSea Therapeutics B.V. since September 2019. Prior to that, he served as Chief Financial Officer of Modus Therapeutics AB (STO: MODTX) from April 2019 to July 2019, Zealand Pharma A/S (CSE: ZELA) from March 2010 to March 2019, and Swedish Orphan International AB (acquired by BioVitrum, now Swedish Orphan Biovitrum AB (publ) (STO:SOBI)) from October 2007 to March 2010. Mats also served as Chief Financial Officer at Active Biotech AB (publ) (STO:ACTI) and Anoto Group AB (STO: ANOT). Earlier in his career, he also served as a management consultant at Gemini Consulting and Ernst & Young. Mats is a board member of Egetis Therapeutics AB (STO: EGTX), Altamira Therapeutics Ltd. (NASDAQ: CYTO) and Pephexia Therapeutics ApS. He holds a B.A. in Business Administration and Economics from the University of Lund and an M.B.A. from the IESE University of Navarra, Barcelona. He was born
in 1965.

Mats is member of Hansa Biopharma’s Audit Committee. Independent of Hansa Biopharma and its executive management. Independent of major shareholders of Hansa Biopharma.

Shareholding: 1,000

Andreas Eggert has served as a member of the Board since May 2018. Andreas has over 25 years of cross-functional leadership experience including commercial operations, launch and portfolio management, brand strategy, market access, and strategic consulting. He has served as the Chief Operating Officer at X-Vax Technology Inc. in the U.S. since October 2018. Previously, he served as Senior Group Vice President, Global Product Strategy & Portfolio Development, and Member of the Corporate Management Committee at H. Lundbeck A/S (CSE: LUN) in Denmark from November 2010 to June 2015, where he was responsible for multiple new product launches and the commercial leadership for shaping the product portfolio and development pipeline. Previously, Andreas served in various senior commercial roles at Wyeth, LLC (acquired by Pfizer Inc. (NYSE: PFE)) in the U.S., Japan and in Germany from 1999 to 2010, including as Vice President & Global Business Manager from September 2005 to April 2010. Earlier in his career, Andreas also was a Management Consultant at A.T. Kearney. He holds an M.B.A. from Azusa Pacific University. He was born in 1967.

Anders Gersel Pedersen, M.D., Ph.D., has served as a member of the Board since May 2018. Anders has over 32 years of experience in the international pharmaceutical industry. From January 2000 to December 2018, he served in various roles at H. Lundbeck A/S in Denmark (CSE: LUN), including most recently as Executive Vice President of Research & Development, where he was responsible for the discovery and development of the product pipeline from preclinical activities to post-launch marketing studies. Prior to that, he served in various roles at Eli Lilly and Company (NYSE: LLY) from August 1988 to December 1999, including most recently as a director overseeing worldwide clinical research in oncology. He is a member of the European Society of Medical Oncology, the International Association for the Study of Lung Cancer and the American Society of Clinical Oncology. Anders serves on the supervisory boards of Avillion LLP, Bavarian Nordic A/S (CSE: BAVA), and Genmab A/S (CSE: GMAB). He received his medical degree and a doctoral degree in neuro-oncology from the University of Copenhagen and a B.Sc. in Business Administration from Copenhagen Business School. He was born in 1951.

Anders is Chair of Hansa’s Scientific Committee, and member of the Remuneration Committee.
Independent of Hansa Biopharma and its executive management. Independent of major shareholders of Hansa Biopharma.

Shareholding: 2,500

Hilary M. Malone, Ph.D., has served as a member of the Board since May 2021. Hilary has over 25 years of experience in global drug development, regulatory and government affairs, manufacturing and commercialization within the pharmaceutical industry. She has served as Chief Executive Officer of a private life sciences company in start-up phase since November 2021. She previously served as Chief Operating Officer and Executive Vice President at Valo Health Inc. from January 2020 to September 2021. Prior to that, Hilary served as the Chief Regulatory Officer and Senior Vice President & Head of Global Regulatory Affairs at Sanofi Inc. (subsidiary of Sanofi SA (Euronext: SAN)). Her previous experience also includes senior regulatory and drug development roles at Reata Pharmaceuticals, Inc. (NASDAQ: RETA), Pfizer Inc. (NYSE:PFE), Wyeth, LLC (acquired by Pfizer Inc.), AstraZeneca plc (LSE: AZN) and GlaxoSmithKline plc (LSE: GSK). Hilary served on the board of Inhibikase Therapeutics (NASDAQ: IKT) from 2016 to 2019. She holds a Ph.D. in Molecular Neuropharmacology and a B.Sc. in Physiology from the University of Dundee, Scotland. She was born in 1965 and is a U.S., U.K., and Irish citizen.